Abrégé

The present disclosure relates to an improved immune cell expressing an antigen-specific receptor such as a CAR or TCR, in which SUV39H1 is inactivated, optionally combined with disruption of the TRAC locus and/or deletion of one or more ITAMs. The disclosure also provides compositions comprising such cells, methods of producing such cells, and uses of such cells in adoptive cell therapy, e.g. in cancer or inflammatory diseases.

Classes IPC  ?

• C07K 14/725 - Récepteurs de lymphocytes-T
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
• A61K 40/32 - Récepteurs des lymphocytes T [TCR]
• A61K 40/42 - Antigènes associés au cancer
• A61P 35/00 - Agents anticancéreux
• C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK

Abrégé

The present disclosure provides tumor neoantigenic peptide sequences and nucleotide sequences encoding such peptide sequences; a vaccine or immunogenic composition capable of raising a specific T-cell response comprising one or more of the neoantigenic peptides, or comprising nucleic acid encoding one or more of the neoantigenic peptides; an antibody, or an antigen-binding fragment thereof, a T cell receptor (TCR), or a chimeric antigen receptor (CAR) that specifically binds such neoantigenic peptides; methods of producing such antibodies, TCRs or CARs; polynucleotides encoding such neoantigenic peptides, antibodies, CARs or TCRs, optionally linked to a heterologous regulatory control sequence; immune cells that specifically bind to such neoantigenic peptides; and dendritic cells or antigen presenting cells that have been pulsed with one or more of the neoantigenic peptides; and methods of using such products in particular therapeutic uses of these products.

Classes IPC  ?

• A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
• A61K 40/15 - Lymphocytes NK [natural-killer]Lymphocytes NKT [natural-killer T]
• A61K 40/31 - Récepteurs antigéniques chimériques [CAR]
• A61K 40/32 - Récepteurs des lymphocytes T [TCR]
• A61K 40/42 - Antigènes associés au cancer
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 35/00 - Agents anticancéreux
• C07K 14/725 - Récepteurs de lymphocytes-T
• C07K 14/74 - Complexe majeur d'histocompatibilité [MHC]
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire

Abrégé

The present disclosure provides tumor neoantigenic peptide sequences and nucleotide sequences encoding such peptide sequences; a vaccine or immunogenic composition capable of raising a specific T-cell response comprising one or more of the neoantigenic peptides, or comprising nucleic acid encoding one or more of the neoantigenic peptides; an antibody, or an antigen-binding fragment thereof, a T cell receptor (TCR), or a chimeric antigen receptor (CAR) that specifically binds such neoantigenic peptides; methods of producing such antibodies, TCRs or CARs; polynucleotides encoding such neoantigenic peptides, antibodies, CARs or TCRs, optionally linked to a heterologous regulatory control sequence; immune cells that specifically bind to such neoantigenic peptides; and dendritic cells or antigen presenting cells that have been pulsed with one or more of the neoantigenic peptides; and methods of using such products in particular therapeutic uses of these products.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 35/00 - Agents anticancéreux
• C07K 14/82 - Produits de traduction des oncogènes

Abrégé

The invention provides compositions and methods for treating a refractory, relapsed or resistant cancer or a chronic infectious disease. In particular the present invention relates to a modified immune cell with reduced SUV39H1 activity, for use in the treatment of a patient suffering from a refractory, relapsed or resistant cancer or suffering from a chronic infectious disease, wherein the cell expresses one or more engineered antigen-specific receptors that bind an antigen associated with the cancer or the chronic infectious disease

Classes IPC  ?

• A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
• A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
• A61K 40/15 - Lymphocytes NK [natural-killer]Lymphocytes NKT [natural-killer T]
• A61K 40/31 - Récepteurs antigéniques chimériques [CAR]
• A61K 40/32 - Récepteurs des lymphocytes T [TCR]
• A61K 40/42 - Antigènes associés au cancer
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 35/00 - Agents anticancéreux
• C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
• C07K 14/725 - Récepteurs de lymphocytes-T
• C07K 14/735 - Récepteurs Fc
• C12N 9/22 - Ribonucléases
• C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées

Abrégé

The invention provides compositions and methods for modulating expression of SUV39H1 using inhibitory or activating polynucleotides based on the sequence of a long noncoding RNA or of a short hairpin RNA (shRNA).

Classes IPC  ?

• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
• A61K 40/31 - Récepteurs antigéniques chimériques [CAR]
• A61K 40/32 - Récepteurs des lymphocytes T [TCR]
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire

Abrégé

The present invention relates to the use of KMT inhibitors and in particular of Suv39h1 inhibitors to increase immune response, and in particular immune cell mediated response, notably elicited by a vaccine or immunogenic composition.

Classes IPC  ?

• A61K 31/546 - Composés contenant des systèmes cycliques thia-5 aza-1 bicyclo [4.2.0] octane, c.-à-d. composés contenant un système cyclique de formule , p. ex. céphalosporines, céfaclor, céphalexine contenant d'autres hétérocycles, p. ex. céphalotine
• A61K 38/00 - Préparations médicinales contenant des peptides
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 35/00 - Agents anticancéreux

Abrégé

The present disclosure provides transmembrane chimeric proteins derived from transposable element (TE)-exon fusion transcripts, as well as nucleic acids, antibodies, CARs, non-HLA restricted TCR and immune cells targeting such chimeric proteins that can be used in cancer therapy.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• C07K 14/725 - Récepteurs de lymphocytes-T
• C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs

Abrégé

wherein said tumor neoantigenic peptide binds to at least one Major Histocompatibility Complex (MHC) molecule of said subject. The present disclosure also relates to tumor neoantigenic peptide obtained according to the present method, vaccine or immunogenic composition, antibodies and immune cells derived thereof and their use in therapy of cancer.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• C07K 14/74 - Complexe majeur d'histocompatibilité [MHC]
• C12N 5/078 - Cellules du sang ou du système immunitaire

Abrégé

The invention provides immune cells defective for SUV39H1 with enhanced properties

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens

Abrégé

The invention provides compositions and methods for treating a refractory, relapsed or resistant cancer or a chronic infectious disease. In particular the present invention relates to a modified immune cell with reduced SUV39H1 activity, for use in the treatment of a patient suffering from a refractory, relapsed or resistant cancer or suffering from a chronic infectious disease, wherein the cell expresses one or more engineered antigen-specific receptors that bind an antigen associated with the cancer or the chronic infectious disease.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• C07K 14/725 - Récepteurs de lymphocytes-T
• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens

Abrégé

The invention provides compositions and methods for treating a refractory, relapsed or resistant cancer or a chronic infectious disease. In particular the present invention relates to a modified immune cell with reduced SUV39H1 activity, for use in the treatment of a patient suffering from a refractory, relapsed or resistant cancer or suffering from a chronic infectious disease, wherein the cell expresses one or more engineered antigen-specific receptors that bind an antigen associated with the cancer or the chronic infectious disease.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• C07K 14/725 - Récepteurs de lymphocytes-T
• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens

Abrégé

The invention provides compositions and methods for modulating expression of SUV39H 1 using inhibitory or activating polynucleotides based on the sequence of a long noncoding RNA or of a short hairpin RNA (shRNA).

Classes IPC  ?

• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens

Abrégé

The invention provides compositions and methods for modulating expression of SUV39H1 using inhibitory or activating polynucleotides based on the sequence of a long noncoding RNA or of a short hairpin RNA (shRNA).

Classes IPC  ?

• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens

Abrégé

The present disclosure relates to an improved immune cell expressing an antigen-specific receptor such as a CAR or TCR, in which SUV39H1 is inactivated, optionally combined with disruption of the TRAC locus and/or deletion of one or more ITAMs. The disclosure also provides compositions comprising such cells, methods of producing such cells, and uses of such cells in adoptive cell therapy, e.g. in cancer or inflammatory diseases.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• C07K 14/725 - Récepteurs de lymphocytes-T
• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens

Abrégé

The present disclosure provides tumor neoantigenic peptide sequences and nucleotide sequences encoding such peptide sequences; a vaccine or immunogenic composition capable of raising a specific T-cell response comprising one or more of the neoantigenic peptides, or comprising nucleic acid encoding one or more of the neoantigenic peptides; an antibody, or an antigen-binding fragment thereof, a T cell receptor (TCR), or a chimeric antigen receptor (CAR) that specifically binds such neoantigenic peptides; methods of producing such antibodies, TCRs or CARs; polynucleotides encoding such neoantigenic peptides, antibodies, CARs or TCRs, optionally linked to a heterologous regulatory control sequence; immune cells that specifically bind to such neoantigenic peptides; and dendritic cells or antigen presenting cells that have been pulsed with one or more of the neoantigenic peptides; and methods of using such products in particular therapeutic uses of these products.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 35/00 - Agents anticancéreux
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs

Abrégé

The present disclosure provides transmembrane chimeric proteins derived from transposable element (TE)-exon fusion transcripts, as well as nucleic acids, antibodies, CARs, non-HLA restricted TCR and immune cells targeting such chimeric proteins that can be used in cancer therapy.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• C07K 1/00 - Procédés généraux de préparation de peptides
• C07K 14/12 - Virus des oreillonsVirus de la rougeole

Abrégé

The present disclosure provides transmembrane chimeric proteins derived from transposable element (TE)-exon fusion transcripts, as well as nucleic acids, antibodies, CARs, non-HLA restricted TCR and immune cells targeting such chimeric proteins that can be used in cancer therapy.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• C07K 14/12 - Virus des oreillonsVirus de la rougeole
• C07K 1/00 - Procédés généraux de préparation de peptides

Abrégé

The present disclosure provides tumor neoantigenic peptide sequences and nucleotide sequences encoding such peptide sequences; a vaccine or immunogenic composition capable of raising a specific T-cell response comprising one or more of the neoantigenic peptides, or comprising nucleic acid encoding one or more of the neoantigenic peptides; an antibody, or an antigen-binding fragment thereof, a T cell receptor (TCR), or a chimeric antigen receptor (CAR) that specifically binds such neoantigenic peptides; methods of producing such antibodies, TCRs or CARs; polynucleotides encoding such neoantigenic peptides, antibodies, CARs or TCRs, optionally linked to a heterologous regulatory control sequence; immune cells that specifically bind to such neoantigenic peptides; and dendritic cells or antigen presenting cells that have been pulsed with one or more of the neoantigenic peptides; and methods of using such products in particular therapeutic uses of these products.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 35/00 - Agents anticancéreux
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs

Abrégé

The present disclosure provides tumor neoantigenic peptide sequences and nucleotide sequences encoding such peptide sequences; a vaccine or immunogenic composition capable of raising a specific T-cell response comprising one or more of the neoantigenic peptides, or comprising nucleic acid encoding one or more of the neoantigenic peptides; an antibody, or an antigen-binding fragment thereof, a T cell receptor (TCR), or a chimeric antigen receptor (CAR) that specifically binds such neoantigenic peptides; methods of producing such antibodies, TCRs or CARs; polynucleotides encoding such neoantigenic peptides, antibodies, CARs or TCRs, optionally linked to a heterologous regulatory control sequence; immune cells that specifically bind to such neoantigenic peptides; and dendritic cells or antigen presenting cells that have been pulsed with one or more of the neoantigenic peptides; and methods of using such products in particular therapeutic uses of these products.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• C07K 4/12 - Peptides ayant jusqu'à 20 amino-acides dans une séquence indéterminée ou partiellement déterminéeLeurs dérivés provenant d'animauxPeptides ayant jusqu'à 20 amino-acides dans une séquence indéterminée ou partiellement déterminéeLeurs dérivés provenant d'humains

Abrégé

The present disclosure provides tumor neoantigenic peptide sequences and nucleotide sequences encoding such peptide sequences; a vaccine or immunogenic composition capable of raising a specific T-cell response comprising one or more of the neoantigenic peptides, or comprising nucleic acid encoding one or more of the neoantigenic peptides; an antibody, or an antigen-binding fragment thereof, a T cell receptor (TCR), or a chimeric antigen receptor (CAR) that specifically binds such neoantigenic peptides; methods of producing such antibodies, TCRs or CARs; polynucleotides encoding such neoantigenic peptides, antibodies, CARs or TCRs, optionally linked to a heterologous regulatory control sequence; immune cells that specifically bind to such neoantigenic peptides; and dendritic cells or antigen presenting cells that have been pulsed with one or more of the neoantigenic peptides; and methods of using such products in particular therapeutic uses of these products.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• C07K 4/12 - Peptides ayant jusqu'à 20 amino-acides dans une séquence indéterminée ou partiellement déterminéeLeurs dérivés provenant d'animauxPeptides ayant jusqu'à 20 amino-acides dans une séquence indéterminée ou partiellement déterminéeLeurs dérivés provenant d'humains

Abrégé

The present invention relates to an improved immune cell expressing an antigen-specific receptor such as a CAR or TCR, in which SUV39H1 is inactivated, optionally combined with disruption of the TRAC locus and/or deletion of one or more ITAMs. The invention also provides compositions comprising such cells, methods of producing such cells, and uses of such cells in adoptive cell therapy, e.g. in cancer or inflammatory diseases.

Classes IPC  ?

• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• C07K 14/725 - Récepteurs de lymphocytes-T

Produits et services

Biological and chemical products for use in the pharmaceutical industry and research; chemical reagents for the manufacture of therapeutic immunotherapy solutions. Pharmaceutical preparations; biological and pharmaceutical preparations; biological and pharmaceutical preparations for cancer and tumor treatment using immunotherapy; therapeutic preparations namely antigens, antibodies, T cells; material, preparations, reagents for products for medical use; antigens, antibodies, cells for therapeutic use. Custom manufacture of pharmaceutical products for therapeutic use in immunotherapy; manufacture of therapeutic solutions namely antigens, antibodies, T cells. Scientific research services for medical purposes; antigen identification, screening and development services; scientific and technological services; scientific laboratory services; providing scientific and medical information with regard to immunotherapy; providing services for identifying, analyzng, authenticating, purifying and developing biological material from a genomic platform; epigenetic antigen screening and identification services for therapeutic research purposes; genomic and epigenetic characterization services for identifying drug candidates in immunotherapy; designing algorithms and models for use in scientific and medical research; computer software platforms enabling the use of algorithms for analyzing cells, antigens, tissue, gene expressions, gene sequences, genome annotations, antigen characteristics and immunological responses; computer software platforms enabling the use of algorithms for forecasting the characteristics of antigens and immunological responses. Providing information in the field of manufacturing pharmaceuticals; providing medical information with regard to immunotherapy.

Produits et services

biological and chemical products for manufacturing and research use in the pharmaceutical industry; chemical reagents for the manufacture of therapeutic immunotherapy solutions pharmaceutical products for use in oncology and immunotherapy; biological and pharmaceutical preparations for the treatment of cancer and tumors; biological and pharmaceutical preparations for cancer and tumor treatment using immunotherapy; therapeutic preparations being solutions, namely, antigen, antibodies, T-cells in the nature of preparations for treatment of cancer and tumors; biological materials, preparations, reagents being pharmaceutical products for medical use for the treatment of cancer and tumors; diagnostic preparations for medical purposes, namely, antigens, antibodies, cells for therapeutic use Custom manufacture of pharmaceutical products for therapeutic use in immunotherapy; custom manufacture of therapeutic solutions, namely, antigens, antibodies, T cells providing medical information with regard to immunotherapy Scientific research services for medical purposes; scientific research and product development, namely, antigen identification, screening and development services; scientific and technological research services in the field of oncology and immunotherapy; scientific laboratory services; providing scientific and medical research information with regard to immunotherapy; scientific research and development, namely, providing services for identifying, analyzing, authenticating, purifying and developing biological material from a genomic platform; scientific research, namely, epigenetic antigen screening and identification services for therapeutic research purposes; medical research, namely, genomic and epigenetic characterization services for identifying drug candidates in immunotherapy; providing medical and scientific research information, namely, designing algorithms and models for use in scientific and medical research; Providing temporary use of online non-downloadable computer software platforms featuring algorithms for analyzing cells, antigens, tissues, gene expressions, gene sequences, genome annotations, antigen characteristics and immunological responses; Providing temporary use of an online non-downloadable computer software platform for use in forecasting the characteristics of antigens and immunological responses through the use of algorithms

Produits et services

Biological and chemical products for use in the pharmaceutical industry and research; chemical reagents for the manufacture of therapeutic immunotherapy solutions. Pharmaceutical products; biological and pharmaceutical preparations; biological and pharmaceutical preparations for treating cancer and tumors using immunotherapy; preparing therapeutic solutions, namely, antigen, antibodies, T-cells; biological materials, preparations, reagents for medical products; antigens, antibodies, cells for therapeutic use. Custom manufacture of pharmaceutical products for therapeutic use in immunotherapy; manufacturing antigens, antibodies, T-cells; providing information in the field of manufacturing pharmaceuticals. Scientific research services for medical purposes; identifying, screening and developing antigens; scientific and technological services; scientific laboratory services; providing scientific and medical information on immunotherapy; providing services for identifying, analyzng, authenticating, purifying and developing biological material from a genomic platform; epigenetic antigen screening and identification services for therapeutic research purposes; genomic and epigenetic characterization services for identifying drug candidates in immunotherapy; designing algorithms and models for use in scientific and medical research; computer software platforms enabling the use of algorithms for analyzing cells, antigens, tissue, gene expressions, gene sequences, genome annotations, antigen characteristics and immunological responses; computer software platforms enabling the use of algorithms for forecasting the characteristics of antigens and immunological responses. Providing medical information relating to immunotherapy.

Produits et services

Biological and chemical products for use in the pharmaceutical industry and research; chemical reagents for the manufacture of therapeutic immunotherapy solutions. Pharmaceutical products; biological and pharmaceutical preparations; biological and pharmaceutical preparations for the treatment of cancer and tumors using immunotherapy; preparing therapeutic solutions, namely, antigen, antibodies, T-cells; biological materials, preparations, reagents for products for medical use; antigens, antibodies, cells for therapeutic use. Medical apparatus and instruments; apparatus and instruments for carrying out tests and diagnostics for medical use; apparatus and instruments for identifying, screening, analyzing and developing antigens for medical use; medical apparatus for reading of analytical tests. Custom manufacture of pharmaceutical products for therapeutic use in immunotherapy; manufacturing antigens, antibodies, T-cells; providing information in the field of manufacturing pharmaceuticals. Scientific research services for medical purposes; services for identifying, screening and developing antigens; scientific and technological services; scientific laboratory services; providing scientific and medical information with regard to immunotherapy; providing services for the identification, analysis, authentication, purification and development of biological material from a genomic platform; epigenetic antigen identification and screening services for therapeutic research purposes; genomic and epigenetic characterization services for identifying drug candidates in immunotherapy; designing algorithms and models for use in scientific and medical research; services of computer software platforms enabling the use of algorithms for analyzing cells, antigens, tissues, gene expressions, gene sequences, genome annotations, antigen characteristics and immunological responses; services of a computer software platform enabling the use of algorithms for predicting the characteristics of antigens and immunological responses. Providing medical information with regard to immunotherapy.

Produits et services

Biological and chemical preparations for use in the pharmaceutical industry and research; chemical reagents for the manufacture of therapeutic immunotherapy solutions Pharmaceutical products for use in the fields of oncology and immunotherapy; biological and pharmaceutical preparations for treatment of cancer and tumors; biological and pharmaceutical preparations for treating cancer and tumors using immunotherapy; preparing therapeutic preparations being solutions, namely, antigen, antibodies, T-cells in the nature of preparations for treatment of cancer and tumors; biological materials, preparations, reagents being pharmaceutical for products for medical use in the treatment of cancer and tumors; pharmaceutical antigens, antibodies, and cells for therapeutic use Custom manufacture of pharmaceutical products for therapeutic use in immunotherapy; custom manufacturing of antigens, antibodies, T-cells; Providing medical information relating to immunotherapy; information, advice and consulting services related to the field of pharmaceutical products manufacturing Scientific research services, namely medical research; scientific research and product development, namely, identifying, screening and developing antigens; scientific and technological services, namely, scientific research, analysis and testing in the field of oncology and immunotherapy; scientific laboratory services; providing scientific and medical research information on immunotherapy; providing scientific research services for identifying, analyzing, authenticating, purifying and developing biological material from a genomic platform; scientific analysis, namely, epigenetic antigen screening and identification services for therapeutic research purposes; scientific research, namely, genomic and epigenetic characterization services for identifying drug candidates in immunotherapy; designing algorithms and models for use in scientific and medical research; providing temporary use of online non-downloadable computer software platforms enabling the use of algorithms for analyzing cells, antigens, tissue, gene expressions, gene sequences, genome annotations, antigen characteristics and immunological responses; providing temporary use of online non-downloadable computer software platforms enabling the use of algorithms for forecasting the characteristics of antigens and immunological responses Providing medical information relating to immunotherapy

Produits et services

Biological and chemical products for manufacturing and research use in the pharmaceutical industry; chemical reagents for the manufacture of therapeutic immunotherapy solutions Pharmaceutical products for use in oncology and immunotherapy; biological and pharmaceutical preparations for treatment of cancer and tumors; biological and pharmaceutical preparations for the treatment of cancer and tumors using immunotherapy; therapeutic preparations being solutions, namely, antigen, antibodies, T-cells in the nature of preparations for treatment of cancer and tumors; biological materials, preparations, reagents being pharmaceutical for products for medical use in the treatment of cancer and tumors; antigens, antibodies, cells for therapeutic use apparatus and instruments for carrying out tests and diagnostics for medical use, namely, medical imaging, biopsies, genetic and molecular analysis ; medical apparatus and instruments for identifying, screening, and analyzing antigens for medical use; medical apparatus for reading of analytical tests, namely molecular, blood and genetic testing Custom manufacture of pharmaceutical products for therapeutic use in immunotherapy; Custom manufacturing of antigens, antibodies, T-cells; Providing manufacturing information in the field of pharmaceuticals Scientific research services for medical purposes, namely, medical research; Scientific research and development services for identifying, screening and developing antigens; scientific and technological services, namely, scientific research, analysis and testing in the field of oncology and immunotherapy; scientific laboratory services; providing scientific information with regard to immunotherapy; Scientific research and development services, namely, providing services for the identification, analysis, authentication, purification and development of biological material from a genomic platform; Scientific research, namely, epigenetic antigen identification and screening services for therapeutic research purposes; Scientific research, namely, genomic and epigenetic characterization services for identifying drug candidates in immunotherapy; Scientific and medical research services, namely, designing algorithms and models for use in scientific and medical research; Providing temporary use of online non-downloadable computer software platforms featuring algorithms for analyzing cells, antigens, tissues, gene expressions, gene sequences, genome annotations, antigen characteristics and immunological responses; Providing temporary use of an online non-downloadable computer software platform featuring algorithms for predicting the characteristics of antigens and immunological responses Providing medical information with regard to immunotherapy

Abrégé

The present disclosure relates to a method for selecting a tumor neoantigenic peptide wherein said method comprises: - a step of identifying, among mRNA sequences from cancer cells of a subject, a fusion transcript sequence comprising a transposable element (TE) sequence and an exonic sequence, and including an open reading frame (ORF), and - a step of selecting a tumor neoantigenic peptide of at least 8 amino acids, encoded by a part of said ORF of the fusion transcript sequence, wherein said ORF overlaps the junction between the TE and the exonic sequence, is pure TE and/or is non-canonical, and wherein said tumor neoantigenic peptide binds to at least one Major Histocompatibility Complex (MHC) molecule of said subject. The present disclosure also relates to tumor neoantigenic peptide obtained according to the present method, vaccine or immunogenic composition, antibodies and immune cells derived thereof and their use in therapy of cancer.

Classes IPC  ?

• A61K 35/14 - SangSang artificiel
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
• A61P 35/00 - Agents anticancéreux
• A61P 37/04 - Immunostimulants
• C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• C07K 14/725 - Récepteurs de lymphocytes-T
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• C07K 19/00 - Peptides hybrides
• C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
• C12N 15/12 - Gènes codant pour des protéines animales
• C12N 15/13 - Immunoglobulines
• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer

Abrégé

The present disclosure relates to a method for selecting a tumor neoantigenic peptide wherein said method comprises: - a step of identifying, among mRNA sequences from cancer cells of a subject, a fusion transcript sequence comprising a transposable element (TE) sequence and an exonic sequence, and including an open reading frame (ORF), and - a step of selecting a tumor neoantigenic peptide of at least 8 amino acids, encoded by a part of said ORF of the fusion transcript sequence, wherein said ORF overlaps the junction between the TE and the exonic sequence, is pure TE and/or is non-canonical, and wherein said tumor neoantigenic peptide binds to at least one Major Histocompatibility Complex (MHC) molecule of said subject. The present disclosure also relates to tumor neoantigenic peptide obtained according to the present method, vaccine or immunogenic composition, antibodies and immune cells derived thereof and their use in therapy of cancer.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer

Abrégé

The present invention relates to an improved immune cell expressing an antigen-specific receptor such as a CAR or TCR, in which SUV39H1 is inactivated, optionally combined with disruption of the TRAC locus and/or deletion of one or more ITAMs. The invention also provides compositions comprising such cells, methods of producing such cells, and uses of such cells in adoptive cell therapy, e.g. in cancer or inflammatory diseases.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• C07K 14/725 - Récepteurs de lymphocytes-T
• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens

Produits et services

Pharmaceutical products, medical preparations; chemical-pharmaceutical preparations; chemical preparations for pharmaceutical use; chemical preparations for medical use; diagnostic preparations for medical use; medicines for human medicine; remedies for human medicine; pharmaceutical preparations; biological preparations for medical use; capsules for medicines. Medical apparatus and instruments; receptacles for applying medicines; containers especially made for medical waste; diagnostic apparatus for medical use. Medical services; medical analysis services relating to patient treatment (such as X-rays and blood tests); medical analysis services provided by medical laboratories for diagnostic and therapeutic purposes; medical assistance; advice relating to health; health services; medical equipment rental.

Produits et services

(1) Produits pharmaceutiques pour le traitement de tumeurs et de cancers; préparations médicinales à utiliser en oncologie et en l'immunothérapie; préparations biologiques et pharmaceutiques pour traitement par immunothérapie; préparations biologiques et pharmaceutiques pour le traitement de cancer et tumeurs; Préparation de solutions thérapeutiques pour le traitement de maladies infectieuses, auto-immunes et des tumeurs malignes, à savoir antigènes, anticorps, cellules immunitaires ou progénitrices; préparations pour le diagnostic dans les domaines de l'oncologie et de l'immunothérapie. (2) Récipients spéciaux pour déchets médicaux. (1) Services d'analyses médicales pour le diagnostic et le traitement dans les domaines de l'oncologie et de l'immunothérapie; services d'analyses médicales fournis par des laboratoires médicaux à des fins diagnostiques et thérapeutiques; conseils en matière d'immunothérapie et de services d'immunothérapie; location d'équipements médicaux.

Produits et services

Pharmaceutical products for the treatment of cancerous tumors and auto-immune or infectious diseases; chemical preparations for pharmaceutical use for the treatment of cancerous tumors and auto-immune or infectious diseases; chemical preparations for medical use for the treatment of cancerous tumors and auto-immune or infectious diseases; diagnostic preparations for medical use for the treatment of cancerous tumors and auto-immune or infectious diseases Medical services